Egalet signs agreement with Septodont

Under this agreement Septodont will promote SPRIX (ketorolac tromethamine) Nasal Spray exclusively to dentists in the United States using its focused specialty sales force. Under the terms of the agreement, Egalet will receive an upfront licensing fee, earn sales-based milestones and share in profits from net sales of SPRIX to dentists in the U.S.

"Through our partnership with Septodont, we are able to broaden our commercial reach bringing SPRIX Nasal Spray to dentists," said Bob Radie, president and chief executive officer of Egalet. "Given the data published in Postgraduate Medicine that supports the use of SPRIX Nasal Spray as a potent non-opioid option to treat short-term pain following dental procedures, dentists should welcome this effective treatment option for their patients."

This is the second partnership Egalet has entered to expand the commercial access of SPRIX Nasal Spray. Previously Egalet signed an agreement with Teva to market SPRIX Nasal Spray in select territories outside of the United States. Egalet will continue to seek relationships with companies to expand patient access to SPRIX Nasal Spray and its other pain products.

SPRIX Nasal Spray is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level. For full prescribing information on SPRIX, including the Boxed Warning, please visit sprix.com.

A paper titled, "Effect size comparison of ketorolac nasal spray and commonly prescribed oral combination opioids for pain relief after third molar extraction Surgery," by Gwendolyn Niebler, D.O, senior vice president, clinical development and medical affairs, and Jeffrey Dayno, M.D., chief medical officer, at Egalet was published online in the December 2015 issue of Postgraduate Medicine.